Structural development studies of subtype-selective ligands for peroxisome proliferator-activated receptors (PPARs) based on the 3,4-disubstituted phenylpropanoic acid scaffold as a versatile template

PPAR Research

Volumn , Issue , 2008, Pages

  Miyachi, Hiroyuki ^a   Hashimoto, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 [(2 FLUORO 4 TRIFLUOROMETHYLBENZOYLAMINO)METHYL] 4 BUTOXYBENZYL]BUTYRIC ACID; 2 [3 [(2 FLUORO 4 TRIFLUOROMETHYLBENZOYLAMINO)METHYL] 4 METHOXYBENZYL]BUTYRIC ACID; 2 [4 METHOXY 3 (4 TRIFLUOROMETHYLBENZYLCARBAMOYL)PHENYLMETHYL]BUTYRIC ACID; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; CELL NUCLEUS RECEPTOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; L 10191; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TIPP 204; TIPP 401; TROGLITAZONE;

CANCER INHIBITION; DEMENTIA; DRUG ACTIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENANTIOMER; HUMAN; INFLAMMATION; METABOLIC SYNDROME X; NEOPLASM; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION;

EID: 47349085659     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/689859     Document Type: Review

References (45)

1. Chawta A., Repa J. J., Evans R. M., Mangelsdorf D. J., Nuclear receptors and lipid physiology: opening the x-files Science 2001 294 5548 1866 1870
2. McKenna N. J., Lanz R. B., O'Malley B. W., Nuclear receptor coregulators: cellular and molecular biology Endocrine Reviews 1999 20 3 321 344
3. Giguere V., Orphan nuclear receptors: from gene to function Endocrine Reviews 1999 20 5 689 725
4. Banner C. D., Gottlicher M., Widmark E., Sjovall J., Rafter J. J., Gustafsson J. A., A systematic analytical chemistry/cell assay approach to isolate activators of orphan nuclear receptors from biological extracts: characterization of peroxisome proliferator-activated receptor activators in plasma Journal of Lipid Research 1993 34 9 1583 1591
5. Willson T. M., Brown P. J., Sternbach D. D., Henke B. R., The PPARs: from orphan receptors to drug discovery Journal of Medicinal Chemistry 2000 43 4 527 550
6. Keller H., Dreyer C., Medin J., Mahfoudi A., Ozato K., Wahli W., Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers Proceedings of the National Academy of Sciences of the United States of America 1993 90 6 2160 2164
7. Staels B., Auwerx J., Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones Current Pharmaceutical Design 1997 3 1 1 14
8. Okuno A., Tamemoto H., Tobe K., Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats Journal of Clinical Investigation 1998 101 6 1354 1361
9. Lim H., Gupta R. A., Ma W.-G., Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPAR δ Genes & Development 1999 13 12 1561 1574
10. Sznaidman M. L., Haffner C. D., Maloney P. R., Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPAR δ)-synthesis and biological activity Bioorganic & Medicinal Chemistry Letters 2003 13 9 1517 1521
11. Oliver W. R. Jr., Shenk J. L., Snaith M. R., A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport Proceedings of the National Academy of Sciences of the United States of America 2001 98 9 5306 5311
12. Tanaka T., Yamamoto J., Iwasaki S., Activation of peroxisome proliferator-activated receptor δ induces fatty acid β -oxidation in skeletal muscle and attenuates metabolic syndrome Proceedings of the National Academy of Sciences of the United States of America 2003 100 26 15924 15929
13. Dewald O., Sharma S., Adrogue J., Downregulation of peroxisome proliferator-activated receptor- α gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity Circulation 2005 112 3 407 415
14. Mendez M., LaPointe M. C., PPAR γ inhibition of cyclooxygenase-2, PGE 2 synthase, and inducible nitric oxide synthase in cardiac myocytes Hypertension 2003 42 4 844 850
15. Morrison R. F., Farmer S. R., Role of PPAR γ in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis Journal of Biological Chemistry 1999 274 24 17088 17097
16. Huang J.-W., Shiau C.-W., Yang J., Development of small-molecule cyclin D1-ablative agents Journal of Medicinal Chemistry 2006 49 15 4684 4689
17. Sato M., Peroxisome proliferator activated receptor ligands and angiogenesis Nippon Rinsho 2005 63 4 603 608
18. Tan N. S., Michalik L., Desvergne B., Wahli W., Genetic- or transforming growth factor- β 1 -induced changes in epidermal peroxisome proliferator-activated receptor β / δ expression dictate wound repair kinetics Journal of Biological Chemistry 2005 280 18 18163 18170
19. Tan N. S., Michalik L., Di-Poï N., Essential role of Smad3 in the inhibition of inflammation-induced PPAR β / δ expression The EMBO Journal 2004 23 21 4211 4221
20. Burdick A. D., Bility M. T., Girroir E. E., Ligand activation of peroxisome proliferator-activated receptor- β / δ (PPAR β / δ) inhibits cell growth of human N/TERT-1 keratinocytes Cellular Signalling 2007 19 6 1163 1171
21. Hashimoto Y., Miyachi H., Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis Bioorganic and Medicinal Chemistry 2005 13 17 5080 5093
22. Blanquart C., Barbier O., Fruchart J. C., Staels B., Glineur C., Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation Journal of Steroid Biochemistry and Molecular Biology 2003 85 2-5 267 273
23. Murakami K., Tobe K., Ide T., A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor- α (PPAR- α) and PPAR- γ: effect of PPAR- α activation on abnormal lipid metabolism in liver of Zucker fatty rats Diabetes 1998 47 12 1841 1847
24. Nomura M., Kinoshita S., Satoh H., (3-substituted benzyl)thiazolidine-2, 4-diones as structurally new antihyperglycemic agents Bioorganic & Medicinal Chemistry Letters 1999 9 4 533 538
25. Yajima K., Hirose H., Fujita H., Combination therapy with PPAR γ and PPAR α agonists increases glucose-stimulated insulin secretion in db/db mice American Journal of Physiology 2003 284 5 E966 E971
26. Nomura M., Tanase T., Miyachi H., Efficient asymmetric synthesis of (S)-2-ethylphenylpropanoic acid derivative, a selective agonist for human peroxisome proliferator-activated receptor α Bioorganic & Medicinal Chemistry Letters 2002 12 16 2101 2104
27. Miyachi H., Nomura M., Tanase T., Suzuki M., Murakami K., Awano K., Enantio-dependent binding and transactivation of optically active phenylpropanoic acid derivatives at human peroxisome proliferator-activated receptor α Bioorganic & Medicinal Chemistry Letters 2002 12 3 333 335
28. Miyachi H., Nomura M., Tanase T., Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator- activated receptor (PPAR) activators: novel human PPAR α -selective activators Bioorganic & Medicinal Chemistry Letters 2002 12 1 77 80
29. Nomura M., Tanase T., Ide T., Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor α subtype-selective activators Journal of Medicinal Chemistry 2003 46 17 3581 3599
30. Keller H., Devchand P. R., Perroud M., Wahli W., PPAR α structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents Biological Chemistry 1997 378 7 651 655
31. Brown P. J., Winegar D. A., Plunket K. D., A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPAR α agonist with potent lipid-lowering activity Journal of Medicinal Chemistry 1999 42 19 3785 3788
32. Nagasawa M., Ide T., Suzuki M., Pharmacological characterization of a human-specific peroxisome proliferater-activated receptor α (PPAR α) agonist in dogs Biochemical Pharmacology 2004 67 11 2057 2069
33. Miyachi H., Uchiki H., Analysis of the critical structural determinant(s) of species-selective peroxisome proliferator-activated receptor α (PPAR α)-activation by phenylpropanoic acid-type PPAR α agonists Bioorganic & Medicinal Chemistry Letters 2003 13 19 3145 3149
34. Uchiki H., Miyachi H., Molecular modeling study of species-selective peroxisome proliferator-activated receptor (PPAR) α agonist; possible mechanism(s) of human PPAR α selectivity of an α -substituted phenylpropanoic acid derivative (KCL) Chemical and Pharmaceutical Bulletin 2004 52 3 365 367
35. Brown P. J., Smith-Oliver T. A., Charifson P. S., Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library Chemistry & Biology 1997 4 12 909 918
36. Kalypsys, 2004. WO2004092117-A
37. Mahindroo N., Huang C.-F., Peng Y.-H., Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities Journal of Medicinal Chemistry 2005 48 26 8194 8208
38. Oliver W. R. Jr., Shenk J. L., Snaith M. R., A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport Proceedings of the National Academy of Sciences of the United States of America 2001 98 9 5306 5311
39. Sznaidman M. L., Haffner C. D., Maloney P. R., Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPAR δ)-synthesis and biological activity Bioorganic & Medicinal Chemistry Letters 2003 13 9 1517 1521
40. Basséne C. E., Suzenet F., Hennuyer N., Studies towards the conception of new selective PPAR β / δ ligands Bioorganic & Medicinal Chemistry Letters 2006 16 17 4528 4532
41. Weigand S., Bischoff H., Dittrich-Wengenroth E., Minor structural modifications convert a selective PPAR α agonist into a potent, highly selective PPAR δ agonist Bioorganic & Medicinal Chemistry Letters 2005 15 20 4619 4623
42. Epple R., Azimioara M., Russo R., 1,3,5-trisubstituted aryls as highly selective PPAR δ agonists Bioorganic & Medicinal Chemistry Letters 2006 16 11 2969 2973
43. Epple R., Azimioara M., Russo R., 3,4,5-trisubstituted isoxazoles as novel PPAR δ agonists: part 2 Bioorganic & Medicinal Chemistry Letters 2006 16 21 5488 5492
44. Epple R., Russo R., Azimioara M., 3,4,5-trisubstituted isoxazoles as novel PPAR δ agonists: part 1 Bioorganic & Medicinal Chemistry Letters 2006 16 16 4376 4380
45. Xu H. E., Lambert M. H., Montana V. G., Molecular recognition of fatty acids by peroxisome proliferator- activated receptors Molecular Cell 1999 3 3 397 403